← Leaderboards
Robert David Steiner
Oregon Health And Science University
$9,602,991
Attributed
$12,252,863
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,456,499 · 8
By mechanism
U54$6,520,272 · 3
R01$4,517,863 · 1
R44$4,136,457 · 1
R43$198,790 · 1
M01$55,617 · 1
R13$27,500 · 1
Top collaborators
- Devin Thomas Wiley4 shared
- Daniel Chelsky2 shared
- Jean-Baptiste O Roullet2 shared
- Andrew Lim1 shared
Most similar at Oregon Health And Science University
Same institution · by research overlap
- William E Connor$1,861,965
- Jean-Baptiste O Roullet$2,102,469
- K Michael Gibson$9,768,649
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroIsoprenoidPlasmaBrainLeadClinical ResearchCholesterolSterolsRare DiseasesMental RetardationSmith-Lemli-Opitz SyndromeSyndromeResearch PersonnelResponseProgramsAffectHearingMutationCellsNatural HistoryBiochemicalFoundationsInsight
Grant awards (30)
Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease$1,244,790
R44 · FY2025 · NS
Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)$1,449,910
R44 · FY2022 · NS
Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)$1,441,757
R44 · FY2021 · NS
Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)$198,790
R43 · FY2017 · NS
Antioxidant Therapeutic Clinical Trial in Smith-Lemli-Opitz Syndrome$517,545
U54 · FY2013 · HD · contact PI
Sterol and Isoprenoid Diseases Consortium$517,545
U54 · FY2013 · HD
Dietary Cholesterol and Defects in Cholesterol Synthesis$424,500
R01 · FY2013 · HL · contact PI
Smith-Lemli-Opitz syndrome and Inborn Errors of Cholesterol Synthesis$27,500
R13 · FY2013 · HD · contact PI
Sterol and Isoprenoid Diseases Consortium$545,357
U54 · FY2012 · HD
Antioxidant Therapeutic Clinical Trial in Smith-Lemli-Opitz Syndrome$545,357
U54 · FY2012 · HD · contact PI
Dietary Cholesterol and Defects in Cholesterol Synthesis$516,616
R01 · FY2012 · HL · contact PI
Sterol and Isoprenoid Diseases Consortium$553,288
U54 · FY2011 · HD · contact PI
Antioxidant Therapeutic Clinical Trial in Smith-Lemli-Opitz Syndrome$536,288
U54 · FY2011 · HD · contact PI
Dietary Cholesterol and Defects in Cholesterol Synthesis$498,316
R01 · FY2011 · HL · contact PI
Antioxidant Therapeutic Clinical Trial in Smith-Lemli-Opitz Syndrome$687,866
U54 · FY2010 · HD · contact PI
Sterol and Isoprenoid Diseases Consortium$557,866
U54 · FY2010 · HD · contact PI
Dietary Cholesterol and Defects in Cholesterol Synthesis$500,602
R01 · FY2010 · HL · contact PI
Antioxidant Therapeutic Clinical Trial in Smith-Lemli-Opitz Syndrome$130,000
U54 · FY2010 · HD · contact PI
Sterol and Isoprenoid Diseases Consortium$130,000
U54 · FY2010 · HD · contact PI
Sterol and Isoprenoid Diseases Consortium$899,580
U54 · FY2009 · HD · contact PI
Antioxidant Therapeutic Clinical Trial in Smith-Lemli-Opitz Syndrome$899,580
U54 · FY2009 · HD · contact PI
Dietary Cholesterol and Defects in Cholesterol Synthesis$513,304
R01 · FY2009 · HL · contact PI
Dietary Cholesterol and Defects in Cholesterol Synthesis$460,626
R01 · FY2007 · HL · contact PI
Dietary Cholesterol and Defects in Cholesterol Synthesis$20,000
R01 · FY2007 · HL · contact PI
Dietary Cholesterol and Defects in Cholesterol Synthesis$452,415
R01 · FY2006 · HL · contact PI
Dietary Cholesterol and Defects in Cholesterol Synthesis$440,062
R01 · FY2005 · HL
CLINICAL ASPECTS OF C2 AUC PROFILING TO ASSESS NEORAL EXPOSURE$39,685
M01 · FY2005 · RR
Dietary Cholesterol and Defects in Cholesterol Synthesis$422,249
R01 · FY2004 · HL
C2 AUC Profiling to Assess Neoral Exposure$15,932
M01 · FY2004 · RR
Dietary Cholesterol and Defects in Cholesterol Synthesis$269,173
R01 · FY2003 · HL